All comparative amounts in brackets refer to the outcome of InDex overall activities during the corresponding period 2016.
Strengthened patent protection for cobitolimod |
| [17-November-2017] |
| STOCKHOLM, Nov. 17, 2017 /PRNewswire/ --Period July - September 2017
Period January - September 2017
All comparative amounts in brackets refer to the outcome of InDex overall activities during the corresponding period 2016. Significant events during July - September 2017
Significant events after the reporting period
“The work with the CONDUCT study is now entering the next phase, in which all activated clinics should recruit their first patients as soon as possible,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. CEO statement The work with CONDUCT is now entering the next phase, in which all activated clinics should recruit their first patients as soon as possible. The study is open for patients with left-sided moderate to severe active ulcerative colitis. As it is a disease with both active and inactive periods, one must wait until a patient is in an active period before it can qualify to participate in the study. It is more common with active periods during the winter months. InDex employees have visited 25 of the clinics to build on the team spirit from the investigators’ meeting that InDex hosted in Stockholm in March. We see a strong commitment to the study and have had a very positive impression of the clinics during our visits. The same applies to the contract research organization’s local staff who manages the day-to-day contact with the clinics, so-called CRAs. In December, we will gather the CRAs from all the countries again in Stockholm to discuss recruitment strategies and to let them exchange best practices. At the end of October, we also met several of the investigators in the study at UEGW, the annual major European conference for gastroenterologists. The big topic of conversation at the conference was the news that the large US company Celgene has discontinued the development of the substance mongersen due to lack of efficacy in a Phase III study in Crohn’s disease. Mongersen is an oligonucleotide like cobitolimod, but the substances have completely different mechanisms of action, so the news does not affect our assessment of cobitolimod’s chance of success. Since the summer, the patent situation for cobitolimod has been further strengthened through one new use patent in Europe, one in Japan and one in the US. I particularly would like to highlight the US patent as a valuable complement to our existing patent portfolio, as it covers the use of cobitolimod for treatment of ulcerative colitis in patients without a history of steroid use when cobitolimod is not administered in combination with steroids. I look forward to presenting our progress in the CONDUCT study and other areas at the Redeye Life Science Seminar on November 24, where I hope to meet new and old shareholders. For more information: Publication InDex Pharmaceuticals in brief InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com. This information was brought to you by Cision http://news.cision.com The following files are available for download: http://mb.cision.com/Main/9612/2393943/753433.pdf Interim report Q3 2017 InDex Pharmaceuticals http://mb.cision.com/Public/9612/2393943/8483308a622862a4.pdf PR InDex Pharmaceuicals interim report Q3 2017 View original content:http://www.prnewswire.com/news-releases/index-pharmaceuticals-holding-ab-publ-interim-report-january--september-2017-300558457.html SOURCE Index Pharmaceuticals |
